A Randomized Phase I/II Trial of Temozolomide with Concurrent Radiation Followed by Treatment with Temozolomide Alone vs. Combination Treatment with Temozolomide and Thalidomide, Isotretinoin and Celecoxib as Determined by a Factorial Design in the Adjuvant Treatment of Glioblastoma Multiforme.

Trial Profile

A Randomized Phase I/II Trial of Temozolomide with Concurrent Radiation Followed by Treatment with Temozolomide Alone vs. Combination Treatment with Temozolomide and Thalidomide, Isotretinoin and Celecoxib as Determined by a Factorial Design in the Adjuvant Treatment of Glioblastoma Multiforme.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs Temozolomide (Primary) ; Celecoxib; Isotretinoin; Thalidomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2012 New trial record
    • 30 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top